Longitude Capital

The firm is run by co-founders Patrick Enright and Juliet Tammenoms Bakker, who serve as managing directors and co-head the investment committee. Both have been investing in life sciences since before founding Longitude in 2006 — Enright formerly led healthcare investing at Pequot Ventures, and Tammenoms Bakker covered medical devices at ABN AMRO and later joined Pequot as a managing director. The partnership operates a flat decision-making structure, with senior principals and principals sourcing within their clinical or device specialties.

Longitude relies on a physician-and-operator network: the investment team is built around professionals with MDs, PhDs, or operating experience inside pharmaceutical and medtech companies. The firm also maintains relationships with academic tech-transfer offices at major research universities, particularly on the West Coast. Because Longitude does not compete in software or industrials, it often gets the first call from scientific founders and venture-creation firms seeking a dedicated healthcare investor.

Longitude invests across four healthcare verticals: biotechnology, medical devices, healthcare services, and digital health. The firm's device portfolio includes companies such as Ancora Heart (structural heart, acquired by Edwards Lifesciences) and JenaValve (transcatheter valve replacement). The medical device team focuses on 510(k) and PMA-path products with clear clinical-utility advantages, and typically avoids pure hospital capital-equipment plays where purchasing cycles are long and unpredictable.

In biotechnology, Longitude is stage-flexible — the firm commits to preclinical platform companies, Series A through crossover rounds, and occasionally participates in PIPEs for public biotechs. In medical devices, the focus is typically clinical-stage companies that have completed first-in-human data. In healthcare services, Longitude targets growth-stage companies with demonstrated unit economics and a path to operational scale. The firm does not chase pre-revenue services concepts or concept-stage device startups without animal data.

Longitude Capital is a traditional private equity firm that raises capital from institutional limited partners. It is not a single-family office or multi-family office. The firm closed its fourth fund in 2022 at approximately $1.2B, and aggregate capital raised across all vehicles exceeds $3.4B (per the firm's official communications). There is no family office affiliation or evergreen capital structure.

Longitude avoids healthcare areas where the firm believes its specialization provides no advantage. It does not invest in capital-equipment-dependent medtech, late-stage single-asset plays without a novel mechanism of action, or healthcare IT companies that are predominantly workflow-software businesses rather than clinical decision-support tools. The firm also avoids consumer wellness and direct-to-consumer diagnostics, staying strictly within regulated biomedical products and services.

Longitude syndicates regularly but prefers to lead or co-lead rounds in its core biotech and device investments, using lead-investor status to secure board representation. The firm co-invests with crossover funds (for pre-IPO biotechs), traditional venture firms, and, in services, with growth equity investors. The partnership evaluates each syndicate on whether the assembled investor group can support the company through a full clinical and regulatory cycle, not just the current financing round.